AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics
31. Oktober 2024 08:00 ET
|
EvolveImmune
NORTH CHICAGO, Ill. and BRANFORD, Conn., Oct. 31, 2024 (GLOBE NEWSWIRE) -- AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics to...
Exciting Advances in Ulcerative Colitis Treatments: Skyrizi Gains Early Momentum Following FDA Approval in June
01. Oktober 2024 10:51 ET
|
Spherix Global Insights
EXTON, PA, Oct. 01, 2024 (GLOBE NEWSWIRE) -- The past twelve months have been transformative for the rapidly evolving ulcerative colitis (UC) market, with a surge in advanced therapies receiving FDA...
The Highly Anticipated FDA Approvals of Galderma’s Nemolizumab and Eli Lilly’s Lebrikizumab are Expected to Shift Dermatologists’ Perceptions of the Atopic Dermatitis Market
09. September 2024 10:20 ET
|
Spherix Global Insights
EXTON, PA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Since its 2017 debut as the first advanced systemic treatment for atopic dermatitis (AD), Sanofi/Regeneron’s Dupixent has dominated the US market....
Bright Mountain Media Appoints Elaine Riddell as Non-Executive Director Bringing 15 Years of Experience Driving Transformative Growth
04. September 2024 09:00 ET
|
Bright Mountain Media, Inc.
Boca Raton, FL, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bright Mountain Media, Inc. (OTCQB: BMTM) ("Bright Mountain" or the "Company"), a global marketing services platform with current investments in...
Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach
29. Mai 2024 13:46 ET
|
Lynch Carpenter
PITTSBURGH, May 29, 2024 (GLOBE NEWSWIRE) -- Cencora, Inc. recently announced that it suffered from a cybersecurity attack that occurred in February of 2024, which impacted the personal information...
Professional Diversity Network (PDN) Hosts Successful Virtual Career Fair for Women’s History Month
25. März 2024 09:10 ET
|
Professional Diversity Network, Inc.
CHICAGO, March 25, 2024 (GLOBE NEWSWIRE) -- Professional Diversity Network, Inc. (NASDAQ: IPDN) (“PDN” or the “Company”), a developer and operator of online and in-person networks that provide...
Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for the Treatment of Ulcerative Colitis, but Future Projections Reveal a Highly Evolving Market
22. März 2024 10:14 ET
|
Spherix Global Insights
Exton, Pennsylvania, March 22, 2024 (GLOBE NEWSWIRE) -- The end of 2023 introduced several new treatment options for patients suffering from ulcerative colitis (UC). Among them is Eli Lilly’s Omvoh...
US Retinal Specialists Highlight the Greatest Opportunity for Gene Therapies
19. März 2024 14:20 ET
|
Spherix Global Insights
EXTON, PA, March 19, 2024 (GLOBE NEWSWIRE) -- Gene therapies have emerged as a ray of hope, particularly in the realm of eye diseases. The focus on the eye has provided researchers with a promising...
Charting New Paths: Non-TNF's Evolving in Rheumatoid Arthritis Market
23. Februar 2024 13:50 ET
|
Spherix Global Insights
EXTON, PA, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Amidst the array of advanced treatment avenues available for rheumatoid arthritis (RA), ranging from legacy TNF inhibitors and their newer biosimilar...
Subcutaneous Biologics Market Size & Share to Exceed USD 656.3 Billion by 2034, at CAGR of 12.30% - By PMI
08. Februar 2024 16:30 ET
|
PMI
Covina, Feb. 08, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Subcutaneous Biologics Market size was valued at about USD 205.2 Billion in 2024 and expected to grow at CAGR...